European Journal of Rheumatology
Case-Based Review

Dual Biologic Therapy in Patients with Familial Mediterranean Fever and Spondyloarthritis: Case-Based Review


Department of Internal Medicine, Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey

Eur J Rheumatol 2023; 10: 29-33
DOI: 10.5152/EuJRheum.2022.21180
Read: 943 Downloads: 409 Published: 01 January 2023

Patients with familial Mediterranean fever and spondylitis often fail to respond to conventional and biologic therapies. Achieving remission in these patients usually requires conventional and biologic treatment combinations. Combination of biologic agents may be a promising option for patients with familial Mediterranean fever and spondylitis who have refractory disease. Until recently, limited evidence existed regarding the efficacy and safety of this treatment strategy. To address this, our report presented a case series of 4 patients with familial Mediterranean fever and spondylitis who were resistant to standard treatments and in whom remission is achieved only with dual biologic therapy. The authors also conducted a literature search for studies that reported dual biological therapy in inflammatory diseases.

Cite this article as: Yıldırım D, Kardaş RC, Özkızıltaş B, et al. Dual biologic therapy in patients with familial mediterranean fever and spondyloarthritis: case-based review. Eur J Rheumatol 2023;10(1):29-33.

EISSN 2148-4279